Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $29.1 million.

  • Aligos Therapeutics' Operating Expenses rose 3599.07% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.4 million, marking a year-over-year decrease of 1113.98%. This contributed to the annual value of $93.1 million for FY2024, which is 1018.46% down from last year.
  • Per Aligos Therapeutics' latest filing, its Operating Expenses stood at $29.1 million for Q3 2025, which was up 3599.07% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Operating Expenses ranged from a high of $38.3 million in Q4 2021 and a low of $19.5 million during Q2 2025
  • Its 5-year average for Operating Expenses is $26.8 million, with a median of $26.2 million in 2022.
  • Per our database at Business Quant, Aligos Therapeutics' Operating Expenses crashed by 3337.96% in 2022 and then skyrocketed by 3599.07% in 2025.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Operating Expenses stood at $38.3 million in 2021, then tumbled by 31.57% to $26.2 million in 2022, then grew by 9.38% to $28.7 million in 2023, then dropped by 26.1% to $21.2 million in 2024, then skyrocketed by 37.33% to $29.1 million in 2025.
  • Its Operating Expenses stands at $29.1 million for Q3 2025, versus $19.5 million for Q2 2025 and $19.6 million for Q1 2025.